World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 3.454
Year - 2024
Volume: 3; Issue: 4
Page: 466-491

ADVANCEMENTS AND CHALLENGES IN GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS

Subhasish Saha[1], Anil P. Sao[2], Jagjot Gautam[3], Vikas Kumar Roy[4] and Amrit Paul*[5]

Asst Prof[1], Assoc Prof[2], Lecturer[3], Students[4], Asst Prof*[5]

Department of Pharmaceutics[1], Department of Pharmaceutical Chemistry[2], Department of Pharmaceutical Chemistry[3], Department of Pharmacology*[5]

[1,2,3,4,5]Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107.

Article Received: 14 July 2024 || ***Article Revised: 03 August 2024*** || ***Article Accepted: 27 August 2024***

***Corresponding Author: Amrit Paul**
Assistant Professor, Department of Pharmacology, Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107.
DOI: https://doi.org/10.5281/zenodo.13626305

How to cite this Article: Subhasish Saha, Anil P. Sao, Jagjot Gautam, Vikas Kumar Roy and Amrit Paul. (2024). ADVANCEMENTS AND CHALLENGES IN GASTRO-RETENTIVE DRUG DELIVERY SYSTEMS. World Journal of Pharmaceutical Science and Research, 3(4), 466-491. https://doi.org/10.5281/zenodo.13626305

ABSTRACT

This article examines the development, operation, applications, and future prospects of gastro-retentive drug delivery systems (GRDDS). GRDDS are designed to prolong the half-life of a drug in the stomach, thereby increasing its bioavailability and therapeutic efficacy, particularly for drugs absorbed in the upper gastrointestinal tract. Among the various GRDDS types whose formulation processes, methods of evaluation, and clinical uses are covered are floating, bioadhesive, swelling, and expandable systems. The review highlights the challenges of developing effective GRDDSs, such as ensuring system biocompatibility and controlling drug release characteristics. Future advancements in GRDDS technology are also being researched in an attempt to improve patient compliance and treatment outcomes.

KEYWORDS: Gastro-retentive drug delivery systems, GRDDS, drug delivery, floating systems, bioadhesive systems, swelling systems, expandable systems, drug bioavailability, therapeutic efficacy.

INTRODUCTION

Background Information

Drug delivery systems (DDS) are technologically advanced devices that are intended to safely administer medications to the body at the appropriate times to provide the desired therapeutic effect.[1,2] These systems optimize the medication's release profile, dissemination, acceptance, and outflow with the goal to enhance drug efficacy, limiting side effects, and improving patient compliance.[1,3,4] Among the several DDS, gastro-retentive systems have attracted a lot of interest because of their capacity to extend the period of time that medications are present in the stomach.[5,6] Drug bioavailability is improved by this extended retention, especially for medications that are absorbed mostly in the

stomach or upper portion of the small intestine.[7,8,9] medications that display poor solubility at higher pH values found in the gut, medications with a limited absorption window in the upper gastrointestinal tract, and pharmaceuticals that are unstable in the intestinal or colonic environment benefit from the use of gastro-retentive devices.[10,11,12,13,14]

METHODOLOGY

Literature review

The literature search was conducted using multiple electronic databases, including PubMed, Scopus, and Web of Science. These databases were chosen for their comprehensive coverage of biomedical and pharmaceutical research. The search strategy involved using specific keywords and combinations of terms to ensure a thorough and focused retrieval of relevant literature.

Keywords included “gastro-retentive drug delivery systems,” “floating drug delivery,” “bioadhesive systems,” “swelling systems,” “expandable drug delivery,” “pharmacokinetics,” and “bioavailability.” Boolean operators (AND, OR) were used to refine the search results and ensure that all relevant studies were captured. For example, a search string in PubMed might be: “gastro-retentive drug delivery systems” AND (“floating” OR “bioadhesive” OR “swelling” OR “expandable”) AND (“pharmacokinetics” OR “bioavailability”).

Inclusion and Exclusion Criteria

To ensure the quality and relevance of the reviewed studies, specific inclusion and exclusion criteria were established. Inclusion criteria were as follows:

- Why Research released in peer-reviewed journals starting in 2000 to make sure the body of knowledge represents the most recent developments.
- Studies, reviews, and findings from clinical trials that concentrate on the development, assessment, and medical use of gastro-retentive drug delivery systems.
- Research that focuses on the mechanisms, therapeutic results, and pharmacokinetic enhancements related to GRDDS.
- English-language articles to guarantee a thorough comprehension and precise interpretation of the results.

Exclusion criteria were applied to eliminate studies that did not meet the quality and relevance standards. These criteria included:

- Articles written before 2000 should be avoided in favor of more recent research and accurate information.
- Opinion pieces, editorials, letters to the editor, and non-peer-reviewed articles, as these don't offer reliable scientific information.
- Research that don't concentrate on gastro-retentive systems or that don't offer enough information on the causes and effects of GRDDS.

Gastro-Retentive Drug Delivery Systems (GRDDS)

Definition and Types

Gastro-retentive drug shipping structures (GRDDS) are designed to extend the residence time of medication inside the stomach, thereby enhancing drug absorptionand improving bioavailability.[12,15] These systems are especially useful for tablets which might be absorbed usually inside the stomach or the higher a part of the small gut, capsules which might be less soluble or volatile within the intestinal surroundings, and pills that show off a narrow absorption window within

the top gastrointestinal tract.[10,11,12,13,14] The primary kinds of GRDDS consist of floating structures, swelling and expanding systems, bioadhesive systems, and excessive-density structures.[16,17]

Floating Systems

Floating drug delivery systems (FDDS) are designed to remain buoyant in the gastric fluid, thus maintaining the drug in the stomach for an extended period. These systems can be classified into effervescent and non-effervescent (low-density) systems.[18,19]

- **Effervescent Systems:** These systems make use of gasoline-producing retailers consisting of sodium bicarbonate, citric acid, or tartaric acid, which react within the presence of gastric fluid to provide carbon dioxide.[20,21,22,23] The generated gasoline gets trapped in the matrix of the dosage shape, inflicting it to float. Examples encompass drugs and pills that launch carbon dioxide, growing a floating matrix that retains the drug in the belly.[7,21,23,24]
- **Non-Effervescent Systems:** Those systems rely upon low-density polymers or hydrophilic gel-forming retailers such as hydroxypropyl methylcellulose (HPMC), polysaccharides, or certain bioadhesive polymers.[25,26,27] When those polymers come into touch with gastric fluid, they shape a gel-like barrier that reduces the system's density, allowing it to flow at the gastric contents. Such systems can be designed as single-unit or a couple of-unit dosage bureaucracy.[25,26,27]
- **Swelling and Expanding Systems:** These systems are formulated to swell or expand significantly in the stomach, increasing their size and preventing their passage through the pylorus.[23,28,] The enlarged system is retained in the stomach for prolonged periods, allowing for sustained drug release.[29,30]
- **Swelling Systems:** These systems comprise hydrophilic polymers that take in gastric fluid and swell to numerous instances their authentic size.[19] Typically used polymers encompass HPMC, polyethylene oxide, and sodium carboxymethyl cellulose. The swelling movement slows gastric emptying and keeps the gadget inside the belly for an extended period.[19,26]
- **Expanding Systems:** Expanding systems may be designed as unfolding or unfolding dosage forms. Upon achieving the stomach, those structures expand to a size that forestalls them from leaving the belly thru the pylorus.[31,32,33] They regularly include biodegradable polymers or substances that degrade over the years, allowing the system to sooner or later bypass through the gastrointestinal tract.[31,32]
- **Bioadhesive Systems:** Bioadhesive drug transport systems use bioadhesive polymers to stick to the gastric mucosa, thereby prolonging the gastric house time of the drug.[34,35] These structures rely on the adhesive interactions among the polymer and the mucin layer of the stomach lining.[35]
- **Mechanism:** The bioadhesive polymers form non-covalent bonds (hydrogen bonds, electrostatic interactions) with the mucosal surface.[36] Polymers typically utilized in bioadhesive structures include chitosan, polyacrylic acid, and carbopol.[37] The extended adhesion increases the local awareness of the drug on the web page of absorption, enhancing its bioavailability.[35,37]
- **Applications:** Bioadhesive structures may be formulated as tablets, gels, or patches.[37] These structures are particularly useful for delivering drugs that require localized movement in the stomach or have an absorption window in the top gastrointestinal tract.[38]

High-Density Systems

High-density systems are designed to have a density greater than that of the gastric contents, generally greater than 1.5 g/cm³.[39,40] These structures sink to the bottom of the stomach and remain there for an prolonged period, allowing for sustained drug release.[30]

- **Mechanism:** Excessive-density structures use substances which includes barium sulfate, zinc oxide, iron powder, or titanium dioxide to boom the density of the dosage shape.[41,42] The dense nature of these systems ensures that they settle at the bottom of the stomach and resist the herbal peristaltic moves, thereby prolonging gastric retention time.[43,44]
- **Advantages:** These structures are beneficial for drugs which are in the main absorbed in the stomach or for remedies requiring a prolonged nearby effect.[45] Excessive-density structures may be formulated as capsules or pellets and are less dependent on the fed or fasted country of the affected person in comparison to floating systems.[45,46]

Mechanisms of Gastric Retention

Buoyancy

Buoyant systems, additionally referred to as floating drug shipping structures (FDDS), are designed to glide on the floor of gastric fluids, thereby prolonging their gastric residence time and improving the bioavailability of drugs.[23,47,48] These systems utilize mechanisms which includes effervescence or low-density substances to achieve buoyancy.

Effervescent Systems

bubbling floating systems contain gas-generating marketers like sodium bicarbonate, citric acid, or tartaric acid.[23,49,50,51] When those marketers come into contact with gastric fluid, they react to produce carbon dioxide fuel.[23,48] The gas gets trapped in the matrix of the dosage shape, reducing its typical density and allowing it to waft.[7,21,23,24] This mechanism enables maintain the drug within the belly for prolonged intervals, ensuring a sustained launch and advanced absorption.[7,21,23,24] As an example, floating capsules or drugs regularly comprise polymers consisting of hydroxypropyl methylcellulose (HPMC), which shape a gel barrier that traps the generated fuel and keeps the system buoyant.[25,26,27]

Low-Density Systems

Non-bubbling floating systems depend on low-density polymers or hydrophilic gel-forming marketers that swell upon touch with gastric fluid.[25,26,27] These polymers, along with HPMC, polyacrylate, and polyethylene oxide, reduce the density of the system, making it less dense than the gastric fluid and allowing it to flow.[25,26,27] The floating movement allows keep the drug in the belly, bearing in mind managed launch over an extended duration.[25,26,27,43]

Adhesion

Bioadhesive structures make use of mucoadhesive polymers to adhere to the gastric mucosa, thereby prolonging the gastric house time of the drug.[34,35] These structures depend upon the interplay among the polymer and the mucin layer of the belly lining.[37,52]

Mucoadhesive Polymers

Mucoadhesive polymers, such as chitosan, polyacrylic acid, carbopol, and lectins, shape hydrogen bonds, electrostatic interactions, or van der Waals forces with the mucosal floor.[36] These interactions make certain that the drug transport

device stays connected to the gastric mucosa for an extended duration, thereby increasing the nearby awareness of the drug on the absorption web page.[35,37] The prolonged adhesion now not most effective enhances the bioavailability of the drug but additionally gives a sustained release profile.[35,37]

Mechanisms of Adhesion

The adhesion mechanism includes severa steps: The formation of adhesive bonds, the polymer's swelling and wetness in reaction to stomach juices, and the polymer's intimate contact with the mucosalfloor.[53,54] This ensures that the drug delivery mechanism stays in the stomach, accounting for the longer release and absorption of the medicine.[29,30,55] Gels, patches, and capsules are examples of bioadhesive materials that stick to the stomach lining.[37,52]

Size and Density: The size and density of a drug transport machine have a big impact on how long the stomach retains drugs.[29,56,57] The ability of the device to remain in the stomach and withstand gastric emptying is affected by these factors.[58,59]

Size: Growing or swelling stomach systems lengthen, which makes it more challenging for them to cross the pylorus and enter the small intestine.[19] In swelling systems, hydrophilic polymers—which absorb gastric juice and expand to multiple times their actual length—are frequently employed.[19,26] For instance, in addition to HPMC, polyethylene oxide, and sodium carboxymethyl cellulose, swelling structures usually employ polymers.[19,26] The improved length of the device slows down its passage through the gastrointestinal tract, thereby prolonging the gastric retention time.[19,26] Expanding structures, on the other hand, may be designed to unfold or uncoil upon reaching the belly, creating a larger shape that forestalls their transit thru the pylorus.[31]

Density: Excessive-density systems are designed to have a density more than that of gastric contents, generally greater than 1.5 g/cm³.[39,40] Those structures sink to the lowest of the belly and remain there for an extended duration, making sure prolonged gastric retention.[30,45] Excessive-density materials consisting of barium sulfate, zinc oxide, iron powder, and titanium dioxide are used to increase the density of the dosage form.[41,42] The dense nature of those systems ensures that they face up to the herbal peristaltic actions of the belly, thereby preserving their position at the bottom of the gastric hollow space.[43,44]

Advancements in GRDDS

Formulation Innovations: Recent developments in these systems have centered on the creation of new materials and technologies that will enhance the efficiency and functionality of gastro-retentive drug transport structures (GRDDS).[5,13,15] The development of new polymers and structures, primarily based on nanoparticles, has led to significant breakthroughs in the production of GRDDS.[60]

Novel Polymers: The application of contemporary polymers has revolutionized the field of GRDDS.[17,61] Polymers including polyvinyl alcohol (PVA), hydroxypropyl methylcellulose (HPMC), and polyethylene oxide (PEO) are commonly used because they are biocompatible and can create gels.[26,19] The use of naturally occurring polymers like pectin and chitosan, which are low in toxicity and biodegradability, has been studied recently.[62] The development of smart polymers that respond to changes in pH and temperature in their environment is another significant accomplishment.[63,64] By delivering regulated medication release in response to modifications in the stomach environment, these polymers can enhance therapeutic results.[29]

Nanoparticle-Based Systems: Thanks to nanotechnology, GRDDS uses nanoparticles to improve the solubility, stability, and bioavailability of medications.[15,65,66] It is feasible to create nanoparticles that have mucoadhesive properties, which allow them to adhere to the mucosa of the stomach and prolong the stomach's residence time.[67,68,69] Moreover, two additional advantages of nanoparticle-based systems are customized drug delivery and defense against medication deterioration in the acidic stomach environment.[71,72,70] Alginate nanoparticles, for example, have been used to increase the bioavailability of poorly soluble drugs by shielding them from the harsh gastrointestinal environment.[73,74,75,76]

Drug Release Mechanisms: The development of drug release mechanisms has been fueled by the need for focused and regulated pharmaceutical delivery.[37,77,78] These mechanisms enable the medication to be released at a predetermined rate and provide long-lasting therapeutic effects.[4,79,80,81]

Controlled Release Systems: Controlled release systems allow drugs to be released gradually and at a steady pace over a long period of time.[82,83,84] Hydrophilic polymers can be used to achieve this, as they produce a gel barrier that expands in the presence of gastric fluid to control the transit of medications.[61,85,86,87] Multiparticulate systems are a relatively new invention. They combine multiple small units containing medication into a single dosage form.[88,89] This technique gives you more precise control over the kinetics of medicine delivery while reducing the likelihood of dose dumping.[80,90,91]

Targeted Drug Delivery: By delivering the medication precisely to the site of action, targeted drug delivery systems seek to reduce systemic adverse effects.[3,92,93] Targeting in GRDDS can be accomplished by using ligands that attach to particular stomach mucosal receptors.[15,94,95,96] For instance, the use of folate-conjugated nanoparticles to target stomach cancer cells has improved the effectiveness of chemotherapy drugs while lowering their toxicity to healthy organs.[97,98,99,100] Another interesting method for targeted drug administration in GRDDS is the use of magnetic nanoparticles that can be steered to specific areas using an external magnetic field (Gupta & Gupta, 2005).[104,105,102,103,101]

Technology Integration: Innovative technology integration, such as 3D printing, has opened up new avenues for GRDDS development.[106,104] It is possible to precisely design complex drug delivery systems with distinct sizes, shapes, and drug release characteristics with the aid of 3D printing.[107,108,109]

3D Printing: The technology known as additive manufacturing, or 3D printing, enables the layer-by-layer construction of intricate drug delivery systems.[111,111,112] This method allows the creation of systems with varying surface areas, porosities, and densities to customize drug release patterns. For instance, 3D-printed floating tablets with a hollow core have been developed to boost buoyancy and prolong stomach retention.[111,114,115,116] It is possible to create combination medications that print many medications in one dose form, increasing patient compliance and producing synergistic benefits.[111]

Microencapsulation and Coating Technologies: Drugs have been protected against stomach acid using coating and microencapsulation methods, which also provide controlled release.[117,118,119] Medication encapsulation in protective polymer membranes is made possible by a number of techniques, including spray drying, fluidized bed coating, and

coagulation.[119–120] These coatings' capacity to degrade at specific pH levels means that the medication won't be released until it reaches its intended location.[119]

Clinical Trials and Studies: Recent clinical trials and investigations have demonstrated the efficacy and safety of GRDDS in a variety of medicinal applications.[17,121,122] These studies provide valuable insights into the clinical performance of GRDDS and highlight some of its potential benefits.[122,123]

Clinical Trials on Floating Systems: Drugs having limited absorption windows in the upper gastrointestinal tract can have their bioavailability greatly increased using floating drug delivery systems, according to clinical investigations.[128,129,130,126,127] For instance, a clinical research on floating tablets of metformin showed that the medicine maintained a constant plasma concentration for a longer length of time, improving glycemic control in diabetic patients.[131,132,133] In a similar vein, it was discovered that ciprofloxacin floating capsules improved the antibiotic's absorption and therapeutic efficacy in individuals suffering from gastrointestinal illnesses.[134,135,136]

Bioadhesive Systems in Clinical Practice: Clinical settings have been used to evaluate the ability of bioadhesive drug delivery systems to enhance medicine absorption and provide long-lasting therapeutic benefits.[137–138] In a clinical study, individuals with hypertension showed longer stomach retention and improved blood pressure control while taking the antihypertensive drug captopril in bioadhesive tablet form.[139–140] Bioadhesive gels and patches, which allow for targeted drug delivery and faster healing, have also being investigated as a potential treatment for gastric ulcers.[51,141,142]

High-Density Systems in Therapeutic Applications: Because they guarantee prolonged medication retention in the stomach, high-density drug delivery systems have been investigated for their potential to treat gastrointestinal problems.[136,143,144] Propranolol, a beta-blocker, showed better control of hypertension and prolonged drug release in clinical trials using high-density tablets.[46,115,146] In order to provide focused and long-lasting therapeutic effects, these devices have also been investigated for the delivery of anti-inflammatory medications to patients with stomach inflammation.[46,115,136,146]

Challenges in GRDDS

Gastro-retentive drug delivery systems (GRDDS) offer effective means of improving pharmaceutical bioavailability and therapeutic efficacy by prolonging stomach retention.[5,121,147] A few problems must be fixed before these technologies may be used in clinical practice efficiently.

Physiological Variability

Physiological considerations such as individual differences in stomach pH fluctuation, motility, and transit time greatly impede the reliable performance of GRDDS.[5,61,121]

Gastric pH Variability: The stomach's pH fluctuates during the day and between individuals; after meals, it is more neutral (pH 4-6) and more acidic (pH 1.5-3.5) during a fast.[148,149] This heterogeneity affects the solubility and dissolution of pharmaceuticals, which in turn affects the drugs' therapeutic efficacy and absorption.[150,148,149] GRDDS must be designed to maintain drug stability and release characteristics in a range of pH levels in order to ensure uniform drug distribution.[123,148,149,150]

Motility and Transit Time: Individual differences in stomach motility and transit times further complicate the effective administration of drugs utilizing GRDDS.[13,16,121] The speed at which the stomach empties can vary depending on a number of factors, including age, food, and gastrointestinal disorders. This can alter the amount of time that dosage forms remain in the stomach.[13,16,121,151] Fast emptying can reduce the efficacy of floating or bioadhesive systems meant for prolonged retention, whereas delayed emptying may lead to differences in drug release profiles.[13,16,121,151]

Impact on Drug Absorption: Variations in the physiology of the stomach may result in variations in the kinetics of drug absorption, potentially producing unfavorable side effects or suboptimal therapeutic outcomes.[152,153,154,155] Refinement of drug release patterns and customization of GRDDS to account for specific stomach conditions are necessary to overcome these challenges.[156,157,152]

Formulation Stability

Medication formulations must continue to be stable in gastrointestinal settings in order for GRDDS to be effective and safe.[5,17,61,158]

Gastric Environment: The acidic pH, the presence of enzymes (such pepsin), and the rapid turnover of stomach fluid all contribute to the formulation's instability.[159,160,161,158] Medication that is sensitive to acid may release or degrade prematurely in the stomach, reducing its bioavailability and possible therapeutic value.[158,162,163,164] There are two formulation strategies that are used to shield drugs from stomach breakdown and enhance stability during stomach transit: enteric coating and encapsulation within protective matrices.[158,165]

Compatibility with Polymers: Excipients and polymers must be used in the formulation of GRDDS in order to guarantee stability.[5,17,123,166] Polymers must maintain their integrity and functionality in acidic environments in order to facilitate controlled drug release in the targeted gastrointestinal tract area.[87,166,167] Compatibility studies are essential to identify interactions between drug molecules and formulation components that may compromise stability or efficacy.[17,123,166,168]

Long-Term Storage: Additional challenges for GRDDS include stable shelf life and storage conditions.[166,170,156] For extended periods, formulations must maintain both physical and chemical stability to ensure product safety and efficacy until delivery.[166,170,156] Changes in temperature, humidity, and light exposure can speed up the breakdown process, necessitating careful stability testing and packaging solutions.[166,170,156]

Patient Compliance

Patient acceptance and adherence to GRDDS have a major influence on treatment outcomes and therapeutic efficacy.[16,17,171]

Acceptance of Dosage Forms: The design and appearance of GRDDS may have an impact on patients' willingness and ability to comply with treatment regimens.[17,123,172] Numerous characteristics, like as flavor, size, shape, and ease of administration, have a significant impact on patient choice and adherence.[17,123,172] Complicated or unappealing dosage forms may contribute to non-compliance, which can have an adverse influence on treatment effectiveness and patient outcomes.[17,123,172]

Dosage Regimen Complexity: GRDDS patients may require particular administration instructions, such as taking medications before meals or with adequate fluids, to optimize stomach retention and drug absorption.[173,174,175] Patients must be able to accurately follow instructions and comprehend dose regimens in order to achieve therapy goals.[173,174,175] Healthcare practitioners are crucial in educating patients about the benefits and proper use of GRDDS in order to increase patient compliance and treatment adherence.[156,173,174,175] Side Effects and Tolerability Patient compliance may be impacted by GRDDS side effects, such as altered taste perception or gastrointestinal distress.[176,177] Maintaining patient adherence over the course of treatment depends on formulation improvement to reduce side effects and increase tolerability.[176,177,178]

Scalability and Manufacturing

Large-scale manufacturing of GRDDS and its scalability pose serious problems in terms of cost-effectiveness, process optimization, and formulation complexity.[66,179]

Formulation Complexity: GRDDS may necessitate sophisticated formulations and particular production methods in order to achieve the desired drug release patterns and performance attributes.[180] Having robust quality control and process validation processes is essential for increasing production without compromising batch-to-batch consistency.[180]

Process Optimization: Hot-melt extrusion, 3D printing, and spray drying are a few of the production methods used to create GRDDS, which have exact specifications and practical features.[26,181,182,183] Optimizing these procedures for commercial manufacturing requires resolving technical issues with raw material sourcing, equipment scalability, and regulatory compliance.[182,183]

Cost Considerations: The cost of raw materials, manufacturing tools, and quality control procedures all have a big impact on how financially viable GRDDS is.[184, 185] In comparison to standard dosage forms, complex formulations and specialized technologies may result in higher manufacturing costs. This means that cost-effective techniques are necessary for scalability and market competitiveness.[184,185]

Future Directions in GRDDS

With great promise for future developments in personalized medicine, regulatory adaptability, and interdisciplinary research collaboration, gastro-retentive drug delivery systems (GRDDS) constitute a vibrant sector.[186,187]

Personalized Medicine

The concept of personalized medicine is tailoring medical care to each patient's specific characteristics while taking lifestyle, environmental, and genetic factors into consideration.[186,187,188,189] By creating customized treatment plans and administering medications with specified targets, GRDDS offer unique opportunities to enhance individualized therapy.[186,187,188,189]

Targeted Drug Delivery: Depending on the unique physiological and pathological conditions of each patient, GRDDS can be designed to target specific gastrointestinal tract areas or deliver medication at a regulated pace.[181,186,187] For example, bioadhesive devices can adhere to injured tissues and deliver drugs locally to treat conditions like stomach ulcers and colorectal cancer.[142,188,189] In order to enhance treatment outcomes, GRDDS can reduce systemic side effects while maximizing drug release patterns and enhancing bioavailability.[16,61]

Patient-Specific Dosage Forms: Dosage forms can be customized to meet the needs of specific patients thanks to advancements in formulation technologies like microencapsulation and 3D printing.[190,191,192] Personalized GRDDS can be created to take into consideration variations in gastric pH, motility patterns, and other physiological factors in order to guarantee precise medication delivery and enhance patient outcomes.[191,193,194] Real-time monitoring of drug release kinetics and patient reaction, enabled by the integration of sensors and smart devices into GRDDS, enables adaptive treatment regimens.[191,195]

Genomics and Biomarkers: Integrating genetic data and biomarker analysis into GRDDS development may improve treatment outcomes and predict patient responses to medication.[15,169,196] The goal of pharmacogenomics research is to identify genetic variations that affect drug toxicity, efficacy, and metabolism. This information helps physicians select the right drug formulations and dosages for individualised care.[196,197,198] Biomarker-based approaches enable the development of targeted GRDDS for precision medicine applications, facilitating the tracking of medication responses and the early identification of disease progression.[196,197]

Regulatory Hurdles

There are challenges with the GRDDS regulatory system because of how complicated the formulation, safety assessment, and market approval processes are.[199,200] To expedite the transfer of state-of-the-art GRDDS technology from laboratory research to clinical usage, these challenges must be addressed.[123,201] Formulation Complexity and Safety: GRDDS often require complex formulations and delivery systems, both of which require extensive safety analyses.[17,42,202] In-depth information on formulation stability, drug release kinetics, and biocompatibility is required by regulatory agencies such as the FDA and EMA in order to assess the efficacy and safety of novel drug delivery systems.[17,42,202] Preclinical studies are required to demonstrate the tissue compatibility, long-term safety, and pharmacokinetic properties of GRDDS in animal models prior to initiating clinical trials.[202,203,204]

Quality Control and Manufacturing Standards: For GRDDS formulations to be consistent and repeatable, standard operating procedures and quality control techniques must be followed.[104,205] Production facilities have to follow stringent guidelines for good manufacturing procedures (GMPs), batch-to-batch uniformity, and equipment calibration in order to meet regulatory standards.[206] Adopting robust quality assurance procedures and conducting validation studies are necessary to protect product integrity during the manufacturing lifecycle and lower the risks related to formulation variability.[206]

Market Approval and Commercialization: The GRDDS is subject to regulatory approval through the use of convoluted approval processes, such as New Drug Applications (NDAs), Clinical Trial Authorizations (CTAs), and Investigational New Drug (IND) applications.[207] Regulatory agencies use data from clinical studies, manufacturing processes, and safety profiles to assess the benefit-risk ratio of GRDDS and provide market authorization.[200,207] Innovative GRDDS technologies that work with regulatory experts and interact with regulatory authorities early on can shorten their commercialization timeframes and expedite the approval process.[200,207]

Interdisciplinary Research: Working together, pharmacologists, engineers, physicians, and other stakeholders can advance GRDDS technology and address complex healthcare concerns.[17,208] Integrating Principles of Engineering: Because they use the principles of process engineering, fluid dynamics, and material science to enhance the effectiveness and efficiency of drug delivery, engineers are crucial to the design and optimization of GRDDS. Thanks

to developments in formulation technologies like nanotechnology and microfluidics, the characteristics of the formulation and the rate of drug release can be precisely regulated.[106,209,210] Engineering and pharmacology research collaborations make it possible to translate scientific discoveries into GRDDS treatments that are realistically achievable.[106,211]

Clinical Validation and Translation: The astute opinions of doctors regarding disease processes, patient care needs, and clinical trial design inform the development and validation of GRDDS in real-world healthcare settings.[212] Multidisciplinary research teams collaborate to conduct clinical trials, assess therapy efficacy, and monitor patient outcomes in order to promote evidence-based practice.[213,214] Including the opinions of healthcare experts and patients ensures that GRDDS solutions meet unmet medical requirements and follow clinical practice guidelines.[106]

Education and Training Initiatives: Through training initiatives and instructional programs, researchers, healthcare professionals, and industry stakeholders are encouraged to work together and share knowledge across disciplines.[217,218] Conferences, workshops, and collaborative research networks foster innovation and facilitate the development of innovative GRDDS technologies that address challenging healthcare problems.[106,208,212] Enough opportunities for mentorship and continuous professional growth allow interdisciplinary teams to drive advancements in medication administration and personalized care.[106,212]

Challenges in Gastroretentive Drug Delivery Systems (GRDDS)

Gastric retentive drug delivery systems (GRDDS) provide a viable alternative for extending the duration of medicine residence time in the stomach while also improving drug bioavailability and therapeutic efficacy.[15,121] However, there are a few challenges that must be solved before they can reach their full therapeutic potential.[121] This article examines the primary problems of GRDDS, such as formulation stability, patient compliance, scalability in production, and physiological variability.[219,220]

Physiological Variability

Individual differences in transit duration, motility, and stomach pH fluctuation are examples of physiological characteristics that significantly impede the development and functioning of GRDDS.[208,212,106]

Gastric pH Variability: People's stomach pH varies a lot day to day; it can be as high as 1.5–3.5 while fasting and as low as neutral or slightly acidic after meals.[221,222,223] This unpredictability may affect the dissolution and release characteristics of drugs from GRDDS, which are often designed to respond to specific pH values for optimal release.[173,209]

Motility and Transit Time: Individual variations in food, age, and health conditions can have an impact on stomach motility and transit times.[17,224] The length of time GRDDS stays in the stomach may vary depending on these variations, which could alter drug absorption and therapeutic outcomes.[13,17] For instance, GRDDS meant for longer retention may be less effective if the stomach empties more quickly.[17,199,225,226]

Formulation Stability

Another important concern is ensuring that GRDDS formulations maintain their stability in the harsh stomach environment, especially in relation to drug integrity and release patterns.[227]

Acidic Environment: The stomach's acidic pH and presence of digestive enzymes can degrade sensitive drugs and alter the properties of polymers used in GRDDS formulations.[13,94] This degradation can compromise drug efficacy and release kinetics, leading to variability in drug absorption and therapeutic outcomes.[228,229]

Interaction with Gastric Contents: Drug release and dissolving rates may be impacted by interactions between GRDDS and stomach contents such food, bile salts, and mucus.[94,199] To guarantee constant function under varying physiological settings, formulation strategies need to take these interactions into consideration.[230,231]

Patient Compliance

Complying with GRDDS may depend on a patient's acceptance, convenience, and adherence to treatment plans, among other factors.[173,201]

Acceptance of Formulations: In contrast to conventional oral medications, GRDDS often include innovative dosage forms including mucoadhesive systems, floating tablets, or multiparticulate formulations.[42,232,233] Patient acceptance may have an effect on treatment adherence; this may vary based on factors such as taste, size, and ease of administration.[234,235,236]

Adherence to Dosage Regimens: Requirements for fasting before to medicine delivery or complex dosing schedules may make it difficult for patients to follow them.[237,238] The failure of patients to adhere to the strict time or food rules may affect the effectiveness of GRDDS therapy outcomes.[17,173]

Scalability and Manufacturing

The complexity of formulation processes and the need for uniform performance between batches present significant challenges to the large-scale manufacturing and scalability of GRDDS.[209,239,240]

Formulation Complexity: Complex approaches such as polymer mixing, coating technologies, and excipient inclusion are often used in the formulation of GRDDS in order to generate acceptable release patterns.[16,17,123] Scaling up these processes without compromising the final product's performance and homogeneity can be challenging from a technological standpoint.[16,17,193]

Quality Control: Strict attention to legal criteria and batch-to-batch homogeneity are necessary for the production of GRDDS.[219, 241] Variations in the raw materials, equipment performance, and environmental conditions may have an impact on the final product's quality and efficacy.[219,241,242]

CONCLUSION

Pharmaceutical research and development must employ multidisciplinary strategies and continuously innovate in order to address the GRDDS's problems, which include physiological variability, formulation stability, patient compliance, and manufacturing scalability. Overcoming these challenges will enable GRDDS to treat a greater range of illnesses while enhancing its efficacy and safety. By advancing knowledge and technology in these areas, pharmaceutical scientists can develop more dependable and patient-friendly drug delivery systems that will ultimately improve patient outcomes and quality of life. In order to get over these challenges and fully utilize GRDDS in modern medicine, industry, academia, and regulatory bodies must continue to collaborate.

REFERENCES

1. Jain KK. An overview of drug delivery systems. Drug delivery systems, 2020: 1-54.
2. Li C, Wang J, Wang Y, Gao H, Wei G, Huang Y, Yu H, Gan Y, Wang Y, Mei L, Chen H. Recent progress in drug delivery. Actapharmaceuticasinica B., 2019 Nov 1; 9(6): 1145-62. Jain KK. An overview of drug delivery systems. Drug delivery systems, 2020: 1-54.
3. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules, 2021 Sep 29; 26(19): 5905.
4. Davoodi P, Lee LY, Xu Q, Sunil V, Sun Y, Soh S, Wang CH. Drug delivery systems for programmed and on-demand release. Advanced drug delivery reviews, 2018 Jul 1; 132: 104-38.
5. Das S, Kaur S, Rai VK. Gastro-retentive drug delivery systems: A recent update on clinical pertinence and drug delivery. Drug Delivery and Translational Research, 2021 Jan 5: 1-29.
6. Dehghan M, Kha F. Gastroretentive drug delivery systems: A patent perspective. International Journal of Health Research, 2009; 2(1).
7. Singh, B. N., & Kim, K. H., Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 2000; 63(3): 235-259.
8. Abuhelwa AY, Williams DB, Upton RN, Foster DJ. Food, gastrointestinal pH, and models of oral drug absorption. European journal of pharmaceutics and biopharmaceutics, 2017 Mar 1; 112: 234-48.
9. Ashford M. Gastrointestinal tract–physiology and drug absorption. Aulton's pharmaceutics e-book: the design and manufacture of medicines, 2017; 300.
10. Shweta, A., Anil, K., &Roop, K. K., Gastroretentive drug delivery systems: a review. Drug Delivery, 2005; 12(3): 161-170.
11. Streubel, A., Siepmann, J., &Bodmeier, R., Gastroretentive drug delivery systems. Expert Opinion on Drug Delivery, 2006; 3(2): 217-233.
12. Badoni A, Ojha A, Gnanarajan G, Kothiyal P. Review on gastro retentive drug delivery system. The pharma innovation, 2012 Oct 1; 1(8, Part A): 32.
13. Gadge G, Sabale V, KHADE A. Current approaches on gastro retentive drug delivery system: an overview. International Journal of Pharmacy Research & Technology (IJPRT), 2019; 9(2): 16-28.
14. More S, Gavali K, Doke O, Kasgawade P. Gastroretentive drug delivery system. Journal of drug delivery and therapeutics, 2018 Jul 14; 8(4): 24-35.
15. Malik R, Garg T, Goyal AK, Rath G. Polymeric nanofibers: targeted gastro-retentive drug delivery systems. Journal of Drug Targeting, 2015 Feb 7; 23(2): 109-24.
16. Jassal M, Nautiyal U, Kundlas J, Singh D. A review: Gastroretentive drug delivery system (grdds). Indian journal of pharmaceutical and biological research, 2015 Jan 1; 3(1): 82.
17. Tripathi J, Thapa P, Maharjan R, Jeong SH. Current state and future perspectives on gastroretentive drug delivery systems. Pharmaceutics, 2019 Apr 20; 11(4): 193.
18. Singh, B. N., & Kim, K. H., Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release, 2000; 63(3): 235-259.
19. Rosa, M., Zia, H., & Rhodes, T., Design and testing in vitro of a bioadhesive and floating drug delivery system for oral application. International Journal of Pharmaceutics, 1994; 105(1): 65-70.

20. Muhamad II, Selvakumaran S, Sis MA, Pa'e N, Salehudin MH. Biopolymers as Potential Carrier for Effervescent Reaction Based Drug Delivery System in Gastrointestinal Condition. Cardiovascular Engineering: Technological Advancements, Reviews, and Applications, 2020: 221-41.
21. Bhargav RK, Parveen R, Verma AK, Shrivastav P. A review on floating drug delivery system.
22. Co A, Mu U. A Comparative Study Of Floating Drug Delivery System Of Metronidazole Formulated Using Effervescent And Non-Effervescent Techniques. Journal of Pharmaceutical & Allied Sciences, 2019 Sep 1; 16(3).
23. Shah SH, Patel JK, Patel NV. Stomach specific floating drug delivery system: A review. Int J Pharm Tech Res, 2009 Jul 1; 1(3): 623-33.
24. Gupta ME, Amulya C, Babu IS. A review on floating drug delivery systems. World J Pharm Res, 2019 Mar 15; 8(6): 1294-302.
25. Iglesias Blanco N, GalbisFuster E, Romero Azogil L, Benito Hernández EM, García Martín MD, Lucas Rodríguez R, Paz Báñez MV. In-Depth Study into Polymeric Materials in Low-Density Gastroretentive Formulations. Pharmaceutics, 2020; 12(7): 636.
26. Iglesias N, Galbis E, Romero-Azogil L, Benito E, Lucas R, García-Martín MG, de-Paz MV. In-depth study into polymeric materials in low-density gastroretentiveformulations. Pharmaceutics, 2020 Jul 7; 12(7): 636.
27. Atyabi, F., Sharma, H. L., Mohammad, H. A., & Fell, J. T., In vivo evaluation of a novel gastro-retentive formulation based on ion exchange resins. Journal of Controlled Release, 1996; 42(2): 105-113.
28. Putheti RR, Patil MC. Pharmaceutical Formulation and development of Floating and Swellable sustained drug delivery systems: a review. e-Journal of Science & Technology, 2009 May 1; 4(2).
29. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems for prolonged gastric residence: an overview. Drug development and industrial pharmacy, 1996 Jan 1; 22(6): 531-9.
30. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Critical Reviews™ in Therapeutic Drug Carrier Systems, 1998; 15(3).
31. Garg, S., & Sharma, S., Gastroretentive drug delivery systems. Business Briefing: Pharmatech, 2003; 160-166.
32. Klausner EA, Lavy E, Friedman M, Hoffman A. Expandable gastroretentive dosage forms. Journal of controlled release, 2003 Jun 24; 90(2): 143-62.
33. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. Journal of controlled release, 2006 Mar 10; 111(1-2): 1-8.
34. Rathee P, Jain M, Garg A, Nanda A, Hooda A. Gastrointestinal mucoadhesive drug delivery system: A review. J Pharm Res, 2011 May; 4(5): 1488-53.
35. Smart, J. D., The basics and underlying mechanisms of mucoadhesion. Advanced Drug Delivery Reviews, 2005; 57(11): 1556-1568.
36. Ugoeze KC. Bioadhesive polymers for drug delivery applications. Bioadhesives in Drug Delivery, 2020 Jun 1: 29-56.
37. Shaikh R, Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. Journal of pharmacy and Bioallied Sciences, 2011 Jan 1; 3(1): 89-100.
38. Ponchel, G., &Irache, J. M., Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Advanced Drug Delivery Reviews, 1998; 34(2-3): 191-219.
39. Hou SY, Cowles VE, Berner B. Gastric retentive dosage forms: a review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2003; 20(6).

40. Hooda A. Gastroretentive drug delivery systems: A review of formulation approaches. The pharma innovation, 2012 Oct 1; 1(8).
41. Nilugal KC. *Evaluation of gastric retention time of various dosage forms in experimental in animals* (Master's thesis, Rajiv Gandhi University of Health Sciences (India)).
42. Mathur P, Jhawat V, Dutt R. New Insights into Gastroretentive Dosage Forms in Delivery of Drugs. Current Nanomedicine (Formerly: Recent Patents on Nanomedicine), 2021 Jul 1; 11(2): 91-101.
43. Moes, A. J., Gastroretentive dosage forms. Critical Reviews in Therapeutic Drug Carrier Systems, 1993; 10(2): 143-195.
44. Singh B, Thakkar HP, Bansal S, Saini S, Bansal M, Srivastava PK. Gastroretentive drug delivery systems. In-Vitro and In-Vivo, 2018 Jun 22; 173-208.
45. Bagul US, Patil RV, Shirsath YA, Nikam AJ, Gujar KN. Stomach specific drug delivery systems: a review. Int J Pharm Res Dev, 2011; 4(4): 147-50.
46. Rouge, N., Buri, P., &Doelker, E., Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 1998; 136(1-2): 117-139.
47. Dixit N. Floating drug delivery system. Journal of current pharmaceutical research, 2011; 7(1): 6-20.
48. Shashank C, Prabha K, Sunil S, Vipin Kumar A. Approaches to increase the gastric residence time: Floating drug delivery systems-A review. Asian J Pharm Clin Res., 2013; 6(3): 1-9.
49. Muhamad II, Selvakumaran S, Sis MA, Pa'e N, Salehudin MH. Biopolymers as Potential Carrier for Effervescent Reaction Based Drug Delivery System in Gastrointestinal Condition. Cardiovascular Engineering: Technological Advancements, Reviews, and Applications, 2020: 221-41.
50. Bhargav RK, Parveen R, Verma AK, Shrivastav P. A Review on floating drug delivery system.
51. Co A, Mu U. A Comparative Study Of Floating Drug Delivery System Of Metronidazole Formulated Using Effervescent And Non-Effervescent Techniques. Journal of Pharmaceutical & Allied Sciences, 2019 Sep 1; 16(3).
52. Gupta PK, Leung SH, Robinson JR. Bioadhesives/mucoadhesives in drug delivery to the gastrointestinal tract. Bioadhesive drug delivery systems, 1990: 65-92.
53. Dodou D, Breedveld P, Wieringa PA. Mucoadhesives in the gastrointestinal tract: revisiting the literature for novel applications. European journal of pharmaceutics and biopharmaceutics, 2005 May 1; 60(1): 1-6. .
54. Peppas NA, BuriPA. Surface, interfacial and molecular aspects of polymer bioadhesion on soft tissues. Journal of Controlled Release, 1985 Nov 1; 2: 257-75.
55. Ponchel, G., &Irache, J. M., Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Advanced Drug Delivery Reviews, 1998; 34(2-3): 191-219.
56. Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert opinion on drug delivery, 2006 Mar 1; 3(2): 217-33.
57. Lopes CM, Bettencourt C, Rossi A, Buttini F, Barata P. Overview on gastroretentive drug delivery systems for improving drug bioavailability. International journal of pharmaceutics, 2016 Aug 20; 510(1): 144-58.
58. ThomasJE. Mechanics and regulation of gastric emptying. Physiological reviews, 1957 Oct 1; 37(4): 453-74.
59. Goyal RK, Guo Y, Mashimo H. Advances in the physiology of gastric emptying. Neurogastroenterology & Motility, 2019 Apr; 31(4): e13546.
60. Choudhary, R. K., Beeraka, S., Sarkar, B. K., Dharmamoorthy, G. and Devhare, L., Optimizing Verapamil Hydrochloride In-situ Delivery: A Strategic Formulation Approach using Box-Behnken Design for Enhanced

Performance and Comprehensive Evaluation of Formulation Parameters. *International Journal of Drug Delivery Technology*, 2024; 14(1): 61-70.

61. Makwana A, Sameja K, Parekh H, Pandya Y. Advancements in controlled release gastroretentive drug delivery system: A review. Journal of Drug Delivery and Therapeutics, 2012 May 14; 2(3).
62. Bansal, A. K., Chawla, G., & Gupta, P., Gastroretentive drug delivery systems and their in vivo success: A recent update. Asian Journal of Pharmaceutical Sciences, 2011; 6(2): 88-99.
63. Joglekar M, Trewyn BG. Polymer-based stimuli-responsive nanosystems for biomedical applications. Biotechnology journal, 2013 Aug; 8(8): 931-45.
64. Yan D, Wang Z, Zhang Z. Stimuli-responsive crystalline smart materials: from rational design and fabrication to applications. Accounts of chemical research, 2022 Mar 16; 55(7): 1047-58.
65. Pal R, Pandey P, Thakur S, Chanana A, Singh RP. Biodegradable polymer's enhancing drug delivery activity in different novel drug delivery system. WJPPS, 2022 Nov 22; 12(1): 2046-69.
66. Herdiana Y. Chitosan nanoparticles for gastroesophageal reflux disease treatment. Polymers, 2023 Aug 20; 15(16): 3485.
67. Tan SL, Billa N. Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. Pharmaceutics, 2021 Oct 31; 13(11): 1817.
68. Sunoqrot S, Hasan L, Alsadi A, Hamed R, Tarawneh O. Interactions of mussel-inspired polymeric nanoparticles with gastric mucin: Implications for gastro-retentive drug delivery. Colloids and Surfaces B: Biointerfaces, 2017 Aug 1; 156: 1-8.
69. Amin MK, Boateng JS. Enhancing stability and mucoadhesive properties of chitosan nanoparticles by surface modification with sodium alginate and polyethylene glycol for potential oral mucosa vaccine delivery. Marine drugs, 2022 Feb 22; 20(3): 156.
70. Mittal R, Patel AP, Jhaveri VM, Kay SI, Debs LH, Parrish JM, Pan DR, Nguyen D, Mittal J, Jayant RD. Recent advancements in nanoparticle based drug delivery for gastrointestinal disorders. Expert opinion on drug delivery, 2018 Mar 4; 15(3): 301-18.
71. Zhang M, Merlin D. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis. Inflammatory bowel diseases, 2018 Jun 8; 24(7): 1401-15.
72. Thakuria A, Kataria B, Gupta D. Nanoparticle-based methodologies for targeted drug delivery—an insight. Journal of Nanoparticle Research, 2021 Apr; 23(4): 87.
73. Li S, Zhang H, Chen K, Jin M, Vu SH, Jung S, He N, Zheng Z, Lee MS. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges. Drug delivery, 2022 Dec 31; 29(1): 1142-9.
74. Severino P, da Silva CF, Andrade LN, de Lima Oliveira D, Campos J, Souto EB. Alginate nanoparticles for drug delivery and targeting. Current pharmaceutical design, 2019 Mar 1; 25(11): 1312-34.
75. Wagle SR, Kovacevic B, Walker D, Ionescu CM, Shah U, Stojanovic G, Kojic S, Mooranian A, Al-Salami H. Alginate-based drug oral targeting using bio-micro/nano encapsulation technologies. Expert Opinion on Drug Delivery, 2020 Oct 2; 17(10): 1361-76.
76. Dodero A, Alberti S, Gaggero G, Ferretti M, Botter R, Vicini S, Castellano M. An up-to-date review on alginate nanoparticles and nanofibers for biomedical and pharmaceutical applications. Advanced Materials Interfaces, 2021 Nov; 8(22): 2100809.

77. Kashkooli FM, Soltani M, Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies. Journal of controlled release, 2020 Nov 10; 327: 316-49.
78. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chemical reviews, 1999 Nov 10; 99(11): 3181-98.
79. Kumar KS, Bhowmik D, Srivastava S, Paswan S, Dutta AS. Sustained release drug delivery system potential. The pharma innovation, 2012 Apr 1; 1(2).
80. Bruschi ML. Strategies to modify the drug release from pharmaceutical systems. Woodhead Publishing, 2015 Jun 16.
81. Tran PH, Tran TT, Park JB, Lee BJ. Controlled release systems containing solid dispersions: strategies and mechanisms. Pharmaceutical research, 2011 Oct; 28: 2353-78.
82. Wani MS, Polshettiwar SA, Chopade VV, Joshi RN, Dehghan MH, Gadkari AA, Chepurwar S, Mute V. Controlled Release System A Review. Pharmaceutical Reviews, 2008; 6(1): 41-6.
83. Jantzen GM, Robinson JR. Sustained-and controlled-release drug delivery systems. Drugs and The Pharmaceutical Sciences, 2002; 121: 501-28.
84. Heng PW. Controlled release drug delivery systems. Pharmaceutical Development and Technology, 2018 Oct 21; 23(9): 833-.
85. Borase CB. Floating systems for oral controlled release drug delivery. Int J Appl Pharm, 2012; 4(2): 1-3.
86. Varma MV, Kaushal AM, Garg A, Garg S. Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. American Journal of drug delivery, 2004 Mar; 2: 43-57.
87. Ravi Kumar MN, Kumar § N. Polymeric controlled drug-delivery systems: perspective issues and opportunities. Drug development and industrial pharmacy, 2001 Jan 1; 27(1): 1-30.
88. Dey NS, Majumdar S, Rao ME. Multiparticulate drug delivery systems for controlled release. Tropical journal of pharmaceutical research, 2008 Sep 11; 7(3): 1067-75.
89. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery: current perspectives. Journal of controlled release, 2009 Mar 4; 134(2): 74-80.
90. Ummadi S, Shravani B, Rao NR, Reddy MS, Sanjeev B. Overview on controlled release dosage form. System, 2013; 7(8): 51-60.
91. Singh SK, Venkateshwaran TG, Simmons SP. Oral controlled drug delivery: quality by design (QbD) approach to drug development. Oral controlled release formulation design and drug delivery: theory to practice, 2010 Sep 20: 279-303.
92. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. International journal of pharmaceutical investigation, 2012 Jan; 2(1): 2.
93. Syed A, Devi VK. Potential of targeted drug delivery systems in treatment of rheumatoid arthritis. Journal of Drug Delivery Science and Technology, 2019 Oct 1; 53: 101217.
94. Patil S, Rathi M, Misra A. Applications of polymers in gastric drug delivery. InApplications of Polymers in Drug Delivery, 2021 Jan 1 (pp. 77-104). Elsevier.
95. Adebisi AO, Conway BR. Modification of drug delivery to improve antibiotic targeting to the stomach. Therapeutic delivery, 2015 Jul 1; 6(6): 741-62.
96. Yang C, Merlin D. Localizing Therapeutics to the Gastrointestinal System. InOrganelle and Molecular Targeting, 2021 Dec 27 (pp. 307-324). CRC Press.

97. Bahrami B, Mohammadnia-Afrouzi M, Bakhshaei P, Yazdani Y, Ghalamfarsa G, Yousefi M, Sadreddini S, Jadidi-Niaragh F, Hojjat-Farsangi M. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biology, 2015 Aug; 36: 5727-42.
98. Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G., Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. Journal of Controlled Release, 2010; 104(2): 203-214.
99. Vllasaliu D, Casettari L, Bonacucina G, Cespi M, Palmieri G, Illum L. Folic acid conjugated chitosan nanoparticles for tumor targeting of therapeutic and imaging agents. Pharm. Nanotechnol, 2013 May 8; 1: 184-203.
100. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Current opinion in chemical biology, 2009 Jun 1; 13(3): 256-62.
101. Vinchurkar K, Sainy J, Khan MA, Sheetal MA, Mishra DK, Dixit P. Features and facts of a gastroretentive drug delivery system-a review. Turkish journal of pharmaceutical sciences, 2022 Aug; 19(4): 476.
102. de Souza MP, Sábio RM, de Cassia Ribeiro T, Dos Santos AM, Meneguin AB, Chorilli M. Highlighting the impact of chitosan on the development of gastroretentive drug delivery systems. International Journal of Biological Macromolecules, 2020 Sep 15; 159: 804-22.
103. Khadam VK, Singh RP, Prajapati D, Yunus M, Prajapat B, Rai SK, Kumari P, Gogoi D. An Updated Comprehensive Review on Novel Drug Delivery Systems (NDDS) In the Pharmaceuticals. Asian Journal of Pharmaceutical Research and Development, 2024 Feb 15; 12(1): 55-64.
104. Turac IR, Porfire A, Iurian S, Crișan AG, Casian T, Iovanov R, Tomuță I. Expanding the Manufacturing Approaches for Gastroretentive Drug Delivery Systems with 3D Printing Technology. Pharmaceutics, 2024 Jun 11; 16(6): 790.
105. Gupta, A. K., & Gupta, M., Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials, 2005; 26(18): 3995-4021. https://doi.org/10.1016/j.biomaterials.2004.10.012
106. Dey A, Singh A, Kurmi BD, Singh D. A Complete Sojourn of Current Trends in Gastro-retentive Drug Delivery System: Recent Advances and Patent Survey. Recent Patents on Nanotechnology, 2024 Jun 1; 18(2): 190-206.
107. Kotta S, Nair A, Alsabeelah N. 3D printing technology in drug delivery: recent progress and application. Current pharmaceutical design, 2018 Nov 1; 24(42): 5039-48.
108. Geraili A, Xing M, Mequanint K. Design and fabrication of drug-delivery systems toward adjustable release profiles for personalized treatment. View, 2021 Oct; 2(5): 20200126.
109. Zeeshan F, Madheswaran T, Pandey M, Gorain B. Three-dimensional (3-D) printing technology exploited for the fabrication of drug delivery systems. Current Pharmaceutical Design, 2018 Nov 1; 24(42): 5019-28.
110. Muhindo D, Elkanayati R, Srinivasan P, Repka MA, Ashour EA. Recent advances in the applications of additive manufacturing (3D printing) in drug delivery: a comprehensive review. AAPS PharmSciTech, 2023 Feb 9; 24(2): 57.
111. Goyanes, A., Buanz, A. B., Basit, A. W., &Gaisford, S., Fused-filament 3D printing (3DP) for fabrication of tablets. International Journal of Pharmaceutics, 2015; 476(1-2): 88-92.
112. Borandeh S, van Bochove B, Teotia A, Seppälä J. Polymeric drug delivery systems by additive manufacturing. Advanced drug delivery reviews, 2021 Jun 1; 173: 349-73.
113. Zhao X, Wei W, Niu R, Li Q, Hu C, Jiang S. 3D printed intragastric floating and sustained-release tablets with air chambers. Journal of pharmaceutical sciences, 2022 Jan 1; 111(1): 116-23.

114. Li Q, Guan X, Cui M, Zhu Z, Chen K, Wen H, Jia D, Hou J, Xu W, Yang X, Pan W. Preparation and investigation of novel gastro-floating tablets with 3D extrusion-based printing. International journal of pharmaceutics, 2018 Jan 15; 535(1-2): 325-32.
115. Alqahtani AA, Mohammed AA, Fatima F, Ahmed MM. Fused deposition modelling 3D-printed gastro-retentive floating device for propranolol hcl tablets. Polymers, 2023 Aug 26; 15(17): 3554.
116. Mohammed AA, Alqahtani AA, Ahmed MM. Design and Fabrication of 3D-Printed Gastric Floating Tablets of Captopril: Effect of Geometry and Thermal Crosslinking of Polymer on Floating behavior and Drug release. Pharmaceutical Development and Technology, 2024 May 7(just-accepted): 1-27.
117. Singh MN, Hemant KS, Ram M, Shivakumar HG. Microencapsulation: A promising technique for controlled drug delivery. Research in pharmaceutical sciences, 2010 Jul; 5(2): 65.
118. Jyothi SS, Seethadevi A, Prabha KS, Muthuprasanna P, Pavitra P. Microencapsulation: a review. Int. J. Pharm. Biol. Sci., 2012; 3(2): 509-31.
119. Fonte, P., Araújo, F., Reis, S., & Sarmento, B., Oral insulin delivery: How far are we? Journal of Diabetes Science and Technology, 2014; 7(2): 520-531.
120. Khandbahale SV. Microencapsulation-A novel approach in drug delivery: A review. Asian Journal of Research in Pharmaceutical Science, 2020; 10(1): 39-50.
121. Mandal UK, Chatterjee B, Senjoti FG. Gastro-retentive drug delivery systems and their in vivo success: A recent update. asian journal of pharmaceutical sciences, 2016 Oct 1; 11(5): 575-84.
122. KUMAR A, SRIVASTAVA R. In vitro in vivo studies on floating microspheres for gastroretentive drug delivery system: a review. Asian Journal of Pharmaceutical and Clinical Research, 2021 Jan 5: 13-26.
123. Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert opinion on drug delivery, 2012 May 1; 9(5): 551-65.
124. Ibrahim M, Naguib YW, Sarhan HA, Abdelkader H. Gastro-retentive oral drug delivery systems: A promising approach for narrow absorption window drugs. Journal of advanced Biomedical and Pharmaceutical Sciences, 2019 Jul 1; 2(3): 98-110.
125. Faizi SM, Rathi PN, Tajane SV, Burghate RM, Wasankar SR. Drug delivery to absorption window through floating microspheres: A Review. Research Journal of Pharmaceutical Dosage Forms and Technology, 2012; 4(3): 135-42.
126. Gupta P, Gnanarajan PK, Kothiyal P. Floating drug delivery system: a review. International Journal of Pharma Research & Review, 2015 Aug; 4(8): 37-44.
127. Kamalakkannan V, Puratchikody A, Prasanth VV, Masilamani K. Enhancement of drugs bioavailability by floating drug delivery system-A review. International Journal of Drug Delivery, 2011 Oct 1; 3(4): 558.
128. Niharika MG, Krishnamoorthy K, Akkala M. Overview on floating drug delivery system. Int J App Pharm, 2018 Oct 4; 10(6): 65-71.
129. Keshari A, Tripathi PK, Srivastava A, Vishwas R. Formulation and evaluation of effervecent floating tablets of antidiabetic drug. Journal of Drug Delivery and Therapeutics, 2015 Nov 15; 5(6): 43-55.
130. Budhwar R, PawanJalwal T. Formulation and Evaluation of Floating Tablet of Metformin Hydrochloride by Using Natural Polymer.

131. Chavanpatil, M. D., Jain, P., Chaudhari, S., Shear, R., &Vavia, P. R., Novel sustained release, swellable and bioadhesivegastroretentive drug delivery system for ofloxacin. International Journal of Pharmaceutics, 2006; 316(1-2): 86-92.
132. Mostafavi A, Emami J, Varshosaz J, Davies NM, Rezazadeh M. Development of a prolonged-release gastroretentive tablet formulation of ciprofloxacin hydrochloride: Pharmacokinetic characterization in healthy human volunteers. International journal of pharmaceutics, 2011 May 16; 409(1-2): 128-36.
133. Deshpande, A. A., Shah, N. H., Rhodes, C. T., &Malick, A. W., Development of a novel controlled-release system for gastric retention. Pharmaceutical Research, 1997; 14(6): 815-819.
134. Verma A, Dubey J, Hegde RR, Rastogi V, Pandit JK. Helicobacter pylori: past, current and future treatment strategies with gastroretentive drug delivery systems. Journal of drug targeting, 2016 Nov 25; 24(10): 897-915.
135. Asati S, Jain S, Choubey A. Bioadhesive or mucoadhesive drug delivery system: a potential alternative to conventional therapy. Journal of Drug Delivery and Therapeutics, 2019 Nov 11; 9(4-A): 858-67.
136. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. International journal of pharmaceutics, 2003 Apr 14; 255(1-2): 13-32.
137. Das U, Wadhwa P, Singh PK, Kalidindi DV, Nagpal K. The role of polymers and excipients for better gastric retention of captopril. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2022; 39(6).
138. Bahadur S, Chanda R, Roy A, Choudhury A, Das S, Saha S. Preparation and evaluation of mucoadhesive microcapsules of captopril for oral controlled release. Research Journal of Pharmacy and Technology, 2008; 1(2): 100-5.
139. Paderni C, Compilato D, Giannola LI, Campisi G. Oral local drug delivery and new perspectives in oral drug formulation. Oral surgery, oral medicine, oral pathology and oral radiology, 2012 Sep 1; 114(3): e25-34.
140. Gupta PK, Leung SH, Robinson JR. Bioadhesives/mucoadhesives in drug delivery to the gastrointestinal tract. Bioadhesive drug delivery systems, 1990: 65-92.
141. Ibrahim M, Naguib YW, Sarhan HA, Abdelkader H. Gastro-retentive oral drug delivery systems: A promising approach for narrow absorption window drugs. Journal of advanced Biomedical and Pharmaceutical Sciences, 2019 Jul 1; 2(3): 98-110.
142. Waqar MA, Mubarak N, Khan AM, Khan R, Shaheen F, Shabbir A. Advanced polymers and recent advancements on gastroretentive drug delivery system; a comprehensive review. Journal of Drug Targeting, 2024 Apr 24: 1-7.
143. Rouge, N., Buri, P., &Doelker, E., Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. International Journal of Pharmaceutics, 1998; 136(1-2): 117-139.
144. Kalra S, Kalra B, Agrawal N. Combination therapy in hypertension: An update. Diabetology& metabolic syndrome, 2010 Dec; 2: 1-1.
145. Adibkia K, Ghanbarzadeh S, Mohammadi G, Atashgah RB, Sabzevari A. Gastro retentive drug delivery systems: A review. Journal of Reports in Pharmaceutical Sciences, 2013 Jul 1; 2(2): 190-204.
146. Alpers DH, Cashman KD. General nutritional principles. Yamada's Textbook of Gastroenterology, 2015 Nov 27: 497-527.
147. Ito, Y., & Tomita, M., pH in the stomach. Journal of Anesthesia, 2013; 27(3): 482-493.
148. Vinarov Z, Abdallah M, Agundez JA, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021 Jul 1; 162: 105812.

149. Pilbrant, Å., & Hjemdahl, P., Gastric emptying in man: An overview of literature with special reference to studies using scintigraphy. Scandinavian Journal of Gastroenterology. Supplement, 1988; 152: 1-11.
150. Shishoo, C. J., Gastroretentive drug delivery systems. Critical Reviews in Therapeutic Drug Carrier Systems, 2003; 20(5): 357-418.
151. Jones CR, Hatley OJ, Ungell AL, Hilgendorf C, Peters SA, Rostami-Hodjegan A. Gut wall metabolism. Application of pre-clinical models for the prediction of human drug absorption and first-pass elimination. The AAPS journal, 2016 May; 18: 589-604.
152. Avvari SK. Application of physiologically based pharmacokinetic (PBPK) modeling to study the impact of Roux-en-Y gastric bypass (RYGB) surgery on the bioavailability of oral antibiotics.
153. Chanda R, Roy A, Bahadur S, Saha S, Das S, Choudhury A. Floating drug delivery: A potential alternative to conventional therapy. International Journal of PharmTech Research, 2010; 2(1): 49-59.
154. Dhiman S, Philip N, Gurjeet Singh T, Babbar R, Garg N, Diwan V, Singh P. An insight on novel approaches & perspectives for gastro-retentive drug delivery systems. Current Drug Delivery, 2023 Jun 1; 20(6): 708-29.
155. Mali R, Patil J. Nanomaterials: An Improvised Drug Delivery System through the Gastroretentive Drug Delivery System. Materials Proceedings, 2023 May 5; 14(1): 63.
156. Vllasaliu, D., Exposito-Harris, R., Heras, A., Casettari, L., Garnett, M., Illum, L., Stolnik, S., Tight junction modulation by chitosan nanoparticles: Comparison with chitosan solution. International Journal of Pharmaceutics, 2014; 462(1-2): 233-237.
157. Tyagi P, Pechenov S, Subramony JA. Oral peptide delivery: Translational challenges due to physiological effects. Journal of Controlled Release, 2018 Oct 10; 287: 167-76.
158. Pawar VK, Meher JG, Singh Y, Chaurasia M, Reddy BS, Chourasia MK. Targeting of gastrointestinal tract for amended delivery of protein/peptide therapeutics: strategies and industrial perspectives. Journal of Controlled Release, 2014 Dec 28; 196: 168-83.
159. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and protein drugs. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2003; 20(2&3).
160. Nazli A, Khan MZ, Rácz Á, Béni S. Acid-sensitive Prodrugs; A Promising Approach for Site-specific and Targeted Drug Release. European Journal of Medicinal Chemistry, 2024 Jul 20: 116699.
161. Gomte SS, Agnihotri TG, Khopade S, Jain A. Exploring the potential of pH-sensitive polymers in targeted drug delivery. Journal of Biomaterials Science, Polymer Edition, 2024 Jan 22; 35(2): 228-68
162. Karimi M, Eslami M, Sahandi-Zangabad P, Mirab F, Farajisafiloo N, Shafaei Z, Ghosh D, Bozorgomid M, Dashkhaneh F, Hamblin MR. pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016 Sep; 8(5): 696-716.
163. Dulin W. Oral targeted drug delivery systems: enteric coating. Oral controlled release formulation design and drug delivery: theory to practice, 2010 Sep 20: 205-23.
164. Ito, Y., & Tomita, M., pH in the stomach. Journal of Anesthesia, 2013; 27(3): 482-493.
165. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci., 2003 Jan 1; 6(1): 33-66.
166. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. Journal of controlled release, 2012 Oct 10; 163(1): 34-45.

167. Uboldi M, Chiappa A, Rossi M, Briatico-Vangosa F, Melocchi A, Zema L. Development of a multi-component gastroretentive expandable drug delivery system (GREDDS) for personalized administration of metformin. Expert Opinion on Drug Delivery, 2024 Jan 2; 21(1): 131-49.
168. Ritger, P. L., & Peppas, N. A., A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. Journal of Controlled Release, 1987; 5(1): 23-36.
169. Singh B, Kaur A, Dhiman S, Garg B, Khurana RK, Beg S. QbD-enabled development of novel stimuli-responsive gastroretentive systems of acyclovir for improved patient compliance and biopharmaceutical performance. AapsPharmscitech, 2016 Apr; 17: 454-65.
170. Kumar, L., Verma, A., Singh, A., &Khursheed, R., Gastroretentive drug delivery system: Current approaches and future perspectives. Journal of Drug Delivery Science and Technology, 2015; 29: 77-94.
171. Chordiya M, Gangurde H, Borkar V. Technologies, optimization and analytical parameters in gastroretentive drug delivery systems. Current science, 2017 Mar 10: 946-53.
172. Kumar MR, Satyanarayana B, Paladugu ND, Neerukondavamsi SM, Pasha SI, Vemireddy SP, Poloju DE. A comprehensive review on gastro retentive drug delivery system. Acta Chimica Pharmaceutica Indica, 2013; 3(2): 149-64.
173. Waldman, S. A., Park, G. R., & Waldman, G. J., Coadministration of magnesium hydroxide/ aluminum hydroxide antacid reduces lomefloxacin bioavailability by 44%. Clinical Pharmacology and Therapeutics, 1997; 62(3): 292-297.
174. Kavitha K. *Targeted Drug Delivery of Anti Cancer Drug by Applying Gastro Retentive Systems and Its Pharmacological Evaluation* (Doctoral dissertation, The Tamil Nadu Dr. MGR Medical University, Chennai).
175. Gadhave, D. G., Nirmal, S. A., Dolas, R. T., et al., Gastroretentive drug delivery system: Current approaches and future perspectives. Journal of Applied Pharmaceutical Science, 2018; 8(10): 162-173.
176. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient preference and adherence, 2013 May 20; 419-34.
177. Nayak AK, Hasnain MS, Laha B, Maiti S, editors. Advanced and Modern Approaches for Drug Delivery. Elsevier; 2023 Jul 29.
178. Augst, A. D., Kong, H. J., & Mooney, D. J., Alginate hydrogels as biomaterials. Macromolecular Bioscience, 2006; 6(8): 623-633.
179. Bhatt P, Patel D, Patel A, Patel A, Nagarsheth A. Oral controlled release systems: current strategies and challenges. Novel Drug Delivery Technologies: Innovative Strategies for Drug Re-positioning, 2019; 73-120.
180. Omachi Y. Gastroretentive Sustained-Release Tablets Combined with a Solid Self-Micro-Emulsifying Drug Delivery System Adsorbed onto Fujicalin®. AAPS PharmSciTech, 2022 Jun 8; 23(5): 157.
181. Kolluru, L. P., Renukuntla, J., Narayana Reddy, K. P., & Ghosh, B., Development and evaluation of gastroretentive floating tablets of levofloxacin hemihydrate: Formulation and in vitro-in vivo evaluations. Drug Development and Industrial Pharmacy, 2020; 46(5): 816-827.
182. Kotreka U, Adeyeye MC. Gastroretentive floating drug-delivery systems: a critical review. Critical Reviews™ in Therapeutic Drug Carrier Systems, 2011; 28(1).

183. Siepmann, J., &Siepmann, F., Mathematical modeling of drug delivery. *International Journal of Pharmaceutics,* 2008; *364*(2): 328-343.
184. Sahu SK, Mishra A. Gastroretentive drug delivery systems: an effective strategy for personalized medicine. *Asian J Pharm Sci*., 2020; 15(6): 743-759.
185. Kumar P, Kumar V. Recent advances in gastroretentive drug delivery systems for personalized therapeutics. *J Control Release,* 2018; 275: 79-95.
186. Bhatt P, Patel R. Development and evaluation of gastroretentive systems for personalized drug delivery: a review. *Curr Drug Deliv*, 2019; 16(3): 216-228.
187. Patel AK, Patel VM. A review: Gastroretentive drug delivery systems and its rational in peptic ulcer treatment. J Pharm SciBioscientific Res., 2012 Aug; 2(4): 179-88.
188. Serrano DR, Kara A, Yuste I, Luciano FC, Ongoren B, Anaya BJ, Molina G, Diez L, Ramirez BI, Ramirez IO, Sánchez-Guirales SA. 3D printing technologies in personalized medicine, nanomedicines, and biopharmaceuticals. Pharmaceutics, 2023 Jan 17; 15(2): 313.
189. Yu, J., Wang, Y., Wang, H., Zhang, Y., Wang, X., Guo, J., . . . & Li, G., Development of a novel gastroretentive sustained-release microsphere system to improve the bioavailability of an opioid receptor agonist for the treatment of opioid dependence. Drug Development and Industrial Pharmacy, 2018; 44(9): 1416-1425.
190. Trenfield SJ, Awad A, Madla CM, Hatton GB, Firth J, Goyanes A, Gaisford S, Basit AW. Shaping the future: recent advances of 3D printing in drug delivery and healthcare. Expert opinion on drug delivery, 2019 Oct 3; 16(10): 1081-94.
191. Singh Y, Pawar VK, Chaurasia M, Chourasia MK. Gastroretentive Delivery: Physicochemical, Biopharmaceutical, Technological, and Regulatory Considerations. In Drug Delivery, 2017 Sep 19 (pp. 65-100). CRC Press.
192. Krishna BM, Patro CS, Ramarao CT, Uppala PK. Strategic Approaches and Evaluation of Gastro Retentive Drug Delivery system-A Review. NeuroQuantology, 2022; 20(7): 757.
193. Schneider F, Koziolek M, Weitschies W. In vitro and in vivo test methods for the evaluation of gastroretentive dosage forms. Pharmaceutics, 2019 Aug 16; 11(8): 416.
194. Marwah, H., Garg, T., Rath, G., Goyal, A. K., &Rath, G., Formulation aspects in the development of gastroretentive dosage forms: A review. International Journal of Pharmaceutical Investigation, 2016; 6(3): 129-140.
195. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacological reviews, 2011 Jun 1; 63(2): 437-59.
196. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annual review of genomics and human genetics, 2014 Aug 31; 15(1): 349-70.
197. Das S, Kaur S, Rai VK. Gastro-retentive drug delivery systems: A recent update on clinical pertinence and drug delivery. Drug Delivery and Translational Research, 2021 Jan 5: 1-29.
198. Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics, 2021 Sep 30; 13(10): 1591.
199. Vishwakarma SK, Mishra JN, Vishwakarma DK. A Review on GRDDS Recent Advances In Drug Delivery Systems And Its Application. World Journal of Pharmaceutical Research, 2021 Jul 14; 10(11): 1159-75.

200. Al-Tayyar, N. A., Mahmoud, A. A., Khalil, E. A., Mandal, U. K., & Fu, Y., Development and evaluation of controlled-release liquid-filled gelatin capsules prepared via coaxial ultrasonic atomization. International Journal of Pharmaceutics, 2016; 506(1-2): 78-86.
201. Herdiana Y, Husni P, Nurhasanah S, Shamsuddin S, Wathoni N. Chitosan-based nano systems for natural antioxidants in breast cancer therapy. Polymers, 2023 Jul 5; 15(13): 2953.
202. Grosso R, de-Paz MV. Thiolated-polymer-based nanoparticles as an avant-garde approach for anticancer therapies—reviewing thiomers from chitosan and hyaluronic acid. Pharmaceutics, 2021 Jun 8; 13(6): 854.
203. Choudhary RK, Beeraka S, Sarkar BK, Dharmamoorthy G, Devhare L. Optimizing Verapamil Hydrochloride In-situ Delivery: A Strategic Formulation Approach using Box-Behnken Design for Enhanced Performance and Comprehensive Evaluation of Formulation Parameters. International Journal of Drug Delivery Technology, 2024; 14(1): 61-70.
204. Lopes, C. M., Bettencourt, C., Rossi, A., Buttini, F., & Barata, P., Overview on gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics, 2019; 569: 118627.
205. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nature reviews Drug discovery, 2004 Dec 1; 3(12): 1023-35.
206. Dhiman S, Philip N, Gurjeet Singh T, Babbar R, Garg N, Diwan V, Singh P. An insight on novel approaches & perspectives for gastro-retentive drug delivery systems. Current Drug Delivery, 2023 Jun 1; 20(6): 708-29.
207. Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory consideration. Expert opinion on drug delivery, 2012 May 1; 9(5): 551-65.
208. Rapolu K, Sanka K, Vemula PK, Aatipamula V, Mohd AB, Diwan PV. Optimization and characterization of gastroretentive floating drug delivery system using Box-Behnken design. Drug development and industrial pharmacy, 2013 Dec 1; 39(12): 1928-35.
209. Singh BN, Kim KH. Drug delivery-oral route. Encyclopedia of pharmaceutical technology, 2002; 1.
210. Vrettos NN, Roberts CJ, Zhu Z. Gastroretentive technologies in tandem with controlled-release strategies: A potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics, 2021 Sep 30; 13(10): 1591.
211. Korylchuk N, Pelykh V, Nemyrovych Y, Didyk N, Martsyniak S. Challenges and Benefits of a Multidisciplinary Approach to Treatment in Clinical Medicine. Journal of Pioneering Medical Sciences, 2024 Jun 30; 13: 1-9.
212. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why?. Quality of Life Research, 2009 Feb; 18: 115-23.
213. Jain NK, Bajwa N, editors. Introduction to Quality by Design (QbD): From Theory to Practice. Springer Nature; 2024.
214. Sharma P, Akram W, Jain V, Tailang M, editors. Smart Nanocarrier for Effective Drug Delivery. CRC Press; 2024 Mar 21.
215. Michael O, Crowley S, Eigenbrode SD, Wulfhorst JD, editors. Enhancing communication & collaboration in interdisciplinary research. Sage publications; 2013 Jul 2.
216. Klein JT. Evaluation of interdisciplinary and transdisciplinary research: a literature review. American journal of preventive medicine, 2008 Aug 1; 35(2): S116-23.

217. Waknis V, Narang AS. Gastroretentive Drug Delivery Systems. Oral Bioavailability and Drug Delivery: From Basics to Advanced Concepts and Applications. 2023 Oct 10: 637-56.
218. Shah HP. Quality by design enabled development and optimization of gastroretentive floating matrix tablets of dipyridamole. Asian Journal of Pharmaceutics (AJP), 2017 Jul 7; 11(02).
219. Labib MH, Jones BJ. The Assessment of Gastrointestinal Function. InScientific Foundations of Biochemistry in Clinical Practice, 1994 Jan 1 (pp. 347-382). Butterworth-Heinemann.
220. Balamuralidhara V, Pramodkumar TM, Srujana N, Venkatesh MP, Gupta NV, Krishna KL, Gangadharappa HV. pH sensitive drug delivery systems: a review. American Journal of drug discovery and development, 2011; 1(1): 24-48.
221. Corstens MN. Encapsulation of Lipids to Delay Lipolysis and Reduce Food Intake: 'From Encapsulate Design towards Human Application'. PQDT-Global. 2018.
222. Mahar KM, Portelli S, Coatney R, Chen EP. Gastric pH and gastric residence time in fasted and fed conscious beagle dogs using the Bravo® pH system. Journal of pharmaceutical sciences, 2012 Jul 1; 101(7): 2439-48.
223. Ahmad S, Singh V, Kushwaha SK. Gastro retentive drug delivery system: A review.
224. Rajmane A, Trivedi R, Nandgude T. A novel approach to enhance gastric retention for better therapeutic activity: Gastro retentive drug delivery system. Research Journal of Pharmacy and Technology, 2022; 15(7): 3324-30.
225. Gupta S, Rajak AK, Yadav K, Pradhan M, Mongia P, Raj R, Minz S. Nanocarriers for Gastro-Retentive Drug Delivery. InSmartNanocarrier for Effective Drug Delivery (pp. 169-198). CRC Press.
226. Moss DM, Siccardi M. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British journal of pharmacology, 2014 Sep; 171(17): 3963-79.
227. Abuhelwa AY, Williams DB, Upton RN, Foster DJ. Food, gastrointestinal pH, and models of oral drug absorption. European journal of pharmaceutics and biopharmaceutics, 2017 Mar 1; 112: 234-48.
228. Bergström CA, Charman WN, Porter CJ. Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Advanced drug delivery reviews, 2016 Jun 1; 101: 6-21.
229. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. International journal of pharmaceutics, 2010 Jun 15; 392(1-2): 1-9.
230. Lodh H, Sheeba FR, Chourasia PK, Pardhe HA, Pallavi N. Floating drug delivery system: A brief review. Asian Journal of Pharmacy and Technology, 2020; 10(4): 255-64.
231. Gunjan GG. Gastro Retentive Floating Drug Delivery System: An Overveiw. Research Journal of Pharmaceutical Dosage Forms and Technology, 2020; 12(3): 213-26.
232. Shariff Z, Kirby D, Missaghi S, Rajabi-Siahboomi A, Maidment I. Patient-centric medicine design: key characteristics of oral solid dosage forms that improve adherence and acceptance in older people. Pharmaceutics, 2020 Sep 23; 12(10): 905.
233. Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert opinion on drug delivery, 2011 Nov 1; 8(11): 1521-9.
234. Wood L. A review on adherence management in patients on oral cancer therapies. European Journal of Oncology Nursing, 2012 Sep 1; 16(4): 432-8.
235. Martin LR, Williams SL, Haskard KB, DiMatteo MR. The challenge of patient adherence. Therapeutics and clinical risk management, 2005 Sep 30; 1(3): 189-99.

236. Schneider SM, Hess K, Gosselin T. Interventions to promote adherence with oral agents. InSeminars in oncology nursing, 2011 May 1 27(2): 133-141. WB Saunders.
237. Chaudhari KD, Nimbalwar MG, Singhal NS, Panchale WA, Manwar JV, Bakal RL. Comprehensive review on characterizations and application of gastro-retentive floating drug delivery system. GSC Advanced Research and Reviews, 2021; 7(1): 035-44.
238. Parikh DC, Amin AF. In vitro and in vivo techniques to assess the performance of gastro-retentive drug delivery systems: a review. Expert opinion on drug delivery, 2008 Sep 1; 5(9): 951-65.
239. Dahmash MT. *Modified drug release oral solid formulations of floating pellets, using extrusion and spheronisation method* (Doctoral dissertation, University of Sunderland).
240. Tambe S, Jain D, Agarwal Y, Amin P. Hot-melt extrusion: Highlighting recent advances in pharmaceutical applications. Journal of Drug Delivery Science and Technology, 2021 Jun 1; 63: 102452.